Group 1 - Pharvaris (NASDAQ: PHVS) is set to release topline results for its Phase 3 trial, Rapide-3, for immediate-release deucrictibant in Q4 2025 [1] - Analysis of clinical trial data and medical literature suggests a favorable chance of success for Pharvaris [1] Group 2 - The author has a background in medicine and statistics, which led to an interest in biotech investing [1]

Core Viewpoint - Pharvaris is advancing its late-stage development of deucrictibant, an oral bradykinin B2 receptor antagonist, targeting unmet needs in bradykinin-mediated diseases, with topline data from the RAPIDe-3 Phase 3 study expected in Q4 2025 and a potential NDA submission in H1 2026 [1][2][4] Group 1: Study and Data - The RAPIDe-3 study has achieved target enrollment, and the topline data announcement is now anticipated in the fourth quarter of 2025 [2] - The study evaluates deucrictibant immediate-release capsules (20 mg) for on-demand treatment of angioedema attacks in approximately 120 participants aged 12 and older, including those with C1 inhibitor deficiency [2][3] - Primary endpoints include time to onset of symptom relief and other measures of symptom resolution and safety [2][3] Group 2: Drug Development - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for rapid treatment [3][4] - The drug has received orphan drug designation from the FDA and the European Commission for treating bradykinin-mediated angioedema [3] Group 3: Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability through oral therapies for bradykinin-mediated angioedema [4] - The company is conducting multiple pivotal Phase 3 studies, including CHAPTER-3 for prevention and RAPIDe-3 for on-demand treatment of HAE attacks [4]

Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][3] Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for the prevention and treatment of bradykinin-mediated angioedema attacks [3] - The company is currently evaluating the efficacy and safety of its lead candidate, deucrictibant, in pivotal Phase 3 studies for both prophylaxis and on-demand treatment of HAE attacks [3] Upcoming Presentations - Pharvaris announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit, scheduled for July 10-13, 2025, in Baltimore, Maryland [1] - Multiple poster presentations will be held on July 11, 2025, featuring various studies related to deucrictibant, including long-term safety and efficacy, disease control, and health-related quality of life improvements in HAE patients [2][4]

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. “Pharvaris embraced ...

Pharvaris (PHVS) FY Conference June 11, 2025 04:00 PM ET Speaker0 All right. Good afternoon, and welcome to our, I think, the final session the conference. And it is my pleasure to introduce Maggie Beller, the head of IR for Verus. Maggie, welcome. I know this is the time I'm hosting you here. And before I go to the Q and A, let me just turn it to you for a quick introduction of the company, and maybe a brief overview about what's exciting ahead, and some of the catalysts and timing for that. Speaker1 Absol ...

Pharvaris (PHVS) Update / Briefing June 04, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Farvaris event. At this time, all attendees are in a listen only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Farvaris website following the conclusion of the event. I'd now like to turn the call over to Maggie Beller, Head Head of Corporate and Investor Communications at Farvaris. Please go ...

Core Insights - Pharvaris is advancing its late-stage clinical development of deucrictibant, a novel oral bradykinin B2 receptor antagonist aimed at treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][18] - The company plans to present pivotal data readouts for deucrictibant in the next 18 months, highlighting its commitment to addressing unmet medical needs in this area [2][4] Prophylaxis - The ongoing Phase 2 CHAPTER-1 open-label extension study shows that oral deucrictibant maintains a low attack rate for over a year and a half, regardless of baseline attack rates [3] - Participants in the CHAPTER-1 study reported significant improvements in health-related quality of life (HRQoL) and treatment satisfaction, with all participants indicating well-controlled HAE [4] - A pharmacokinetics study demonstrated that the extended-release (XR) formulation of deucrictibant supports once-daily dosing, showing a four-fold higher mean plasma concentration than the therapeutic threshold at 24 hours [5][7] On-Demand Treatment - A post-hoc analysis of the RAPIDe-1 and RAPIDe-2 trials indicated that 95-100% of HAE attacks treated with a single dose of deucrictibant achieved symptom relief without recurrence [9] - The median time to onset of symptom relief was reported as 1.1 hours, with 97.8% of attacks achieving relief within 12 hours [10][11] - Deucrictibant was well tolerated across various attack types, including upper airway attacks, with no treatment-related adverse events reported [11] Expansion Beyond HAE - Pharvaris is exploring a novel biomarker assay for diagnosing bradykinin-mediated angioedema, which could enhance the identification and management of related conditions [12] - The company is also assessing the patient experience and outcome measures for AAE-C1INH, aiming to develop a conceptual model to support clinical assessments [14] - A systematic literature review estimated the prevalence of HAE-C1INH in the EU and UK to be between 0.05-0.33 per 10,000 individuals, indicating a significant need for effective treatments [15]

ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be h ...

Pharvaris (PHVS) 2025 Conference May 14, 2025 11:40 AM ET Speaker0 My name is Jeremiah Lorenz. I'm one of the Equity Research Analysts here at Bank of America. It's my pleasure to introduce our next presenting company, Farveris. Today, we'll be joined by CEO, Bernd Modig. Bernd, take it away. Speaker1 Yes. Thank you, and welcome and good morning to Farveris. And I'm going show you a brief presentation. It's only fifteen minutes. So if you have questions or want to follow-up, we invite you to reach out to us ...

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on June 4 at 8:00 ...